Anti-PD-L1 antibodies
AssigneeAgency for Science, Technology and Research
InventorsCheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
Life of this patent
Estimating the term…
Abstract
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.
Claims12
An isolated antibody or antigen binding fragment that specifically binds to human PD-L1, having at least one light chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 18)
- LC-CDR1:
- TGSSSNIGAGYDVH
- (SEQ ID NO:
- 19)
- LC-CDR2:
- GNSNRPS
- (SEQ ID NO:
- 20)
- LC-CDR3:
- QSYDSSLSGSYVV;
- and
- having at least one heavy chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 21)
- HC-CDR1:
- SYAIS
- (SEQ ID NO:
- 22)
- HC-CDR2:
- RIIPILGIANYAQKFQG
- (SEQ ID NO:
- 25)
- HC-CDR3:
- SGHGYSYGAFDY.
A method of treating an infectious disease, comprising administering an antibody or antigen binding fragment to a patient suffering from the infectious disease, wherein the antibody or antigen binding fragment specifically binds to human PD-L1, and comprises:
- at least one light chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 18)
- LC-CDR1:
- TGSSSNIGAGYDVH
- (SEQ ID NO:
- 19)
- LC-CDR2:
- GNSNRPS
- (SEQ ID NO:
- 20)
- LC-CDR3:
- QSYDSSLSGSYVV;
- and
- at least one heavy chain variable region incorporating the following CDRs:
- (SEQ ID NO:
- 21)
- HC-CDR1:
- SYAIS
- (SEQ ID NO:
- 22)
- HC-CDR2:
- RIIPILGIANYAQKFQG
- (SEQ ID NO:
- 25)
- HC-CDR3:
- SGHGYSYGAFDY,
- wherein the infectious disease is influenza.
Dependencies are inferred from the claim text.